1887
Research article Open Access
Like 0

Abstract

Introduction

We compared trivalent inactivated influenza vaccine effectiveness (VE) in preventing outpatient and inpatient influenza cases in Navarre, Spain. During seasons 2010/11 to 2015/16, community-dwelling patients with influenza-like illness aged 50 years or older were tested for influenza when attended by sentinel general practitioners or admitted to hospitals. The test–negative design was used to estimate and compare the VE by healthcare setting. We compared 1,242 laboratory-confirmed influenza cases (557 outpatient and 685 inpatient cases) and 1,641 test-negative controls. Influenza VE was 34% (95% confidence interval (CI): 6 to 54) in outpatients and 32% (95% CI: 15 to 45) in inpatients. VE in outpatients and inpatients was, respectively, 41% (95% CI: –1 to 65) and 36% (95% CI: 12 to 53) against A(H1N1)pdm09, 5% (95% CI: –58 to 43) and 22% (95% CI: –9 to 44) against A(H3N2), and 49% (95% CI, 6 to 73) and 37% (95% CI: 2 to 59) against influenza B. Trivalent inactivated influenza vaccine was not associated with a different probability of hospitalisation among influenza cases, apart from a 54% (95% CI: 10 to 76) reduction in hospitalisation of influenza A(H3N2) cases. On average, influenza VE was moderate and similar in preventing outpatient and inpatient influenza cases over six influenza seasons in patients above 50 years of age. In some instances of low VE, vaccination may still reduce the risk of hospitalisation in older adults with vaccine failure.

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2018.23.2.16-00780
2018-01-11
2018-01-23
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2018.23.2.16-00780
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/23/2/eurosurv-23-2-4.html?itemId=/content/10.2807/1560-7917.ES.2018.23.2.16-00780&mimeType=html&fmt=ahah

References

  1. Glezen WP. Serious morbidity and mortality associated with influenza epidemics. Epidemiol Rev. 1982;4(1):25-44.  https://doi.org/10.1093/oxfordjournals.epirev.a036250  PMID: 6754408 
  2. Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ, et al. Influenza-associated hospitalizations in the United States. JAMA. 2004;292(11):1333-40.  https://doi.org/10.1001/jama.292.11.1333  PMID: 15367555 
  3. Reed C, Chaves SS, Daily Kirley P, Emerson R, Aragon D, Hancock EB, et al. Estimating influenza disease burden from population-based surveillance data in the United States. PLoS One. 2015;10(3):e0118369.  https://doi.org/10.1371/journal.pone.0118369  PMID: 25738736 
  4. Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(1):36-44.  https://doi.org/10.1016/S1473-3099(11)70295-X  PMID: 22032844 
  5. Kissling E, Valenciano M, Buchholz U, Larrauri A, Cohen JM, Nunes B, et al. Influenza vaccine effectiveness estimates in Europe in a season with three influenza type/subtypes circulating: the I-MOVE multicentre case-control study, influenza season 2012/13. Euro Surveill. 2014;19(6):20701.  https://doi.org/10.2807/1560-7917.ES2014.19.6.20701  PMID: 24556348 
  6. Puig-Barberà J, García-de-Lomas J, Díez-Domingo J, Arnedo-Pena A, Ruiz-García M, Limón-Ramírez R, et al. Influenza vaccine effectiveness in preventing influenza A(H3N2)-related hospitalizations in adults targeted for vaccination by type of vaccine: a hospital-based test-negative study, 2011-2012 A(H3N2) predominant influenza season, Valencia, Spain. PLoS One. 2014;9(11):e112294.  https://doi.org/10.1371/journal.pone.0112294  PMID: 25392931 
  7. Havers F, Sokolow L, Shay DK, Farley MM, Monroe M, Meek J, et al. Case-control study of vaccine effectiveness in preventing laboratory-confirmed influenza hospitalizations in older adults, United States, 2010-11. Clin Infect Dis. 2016;63(10):1304-11.  https://doi.org/10.1093/cid/ciw512  PMID: 27486114 
  8. Castilla J, Godoy P, Domínguez A, Martínez-Baz I, Astray J, Martín V, et al. Influenza vaccine effectiveness in preventing outpatient, inpatient, and severe cases of laboratory-confirmed influenza. Clin Infect Dis. 2013;57(2):167-75.  https://doi.org/10.1093/cid/cit194  PMID: 23532475 
  9. Darvishian M, Bijlsma MJ, Hak E, van den Heuvel ER. Effectiveness of seasonal influenza vaccine in community-dwelling elderly people: a meta-analysis of test-negative design case-control studies. Lancet Infect Dis. 2014;14(12):1228-39.  https://doi.org/10.1016/S1473-3099(14)70960-0  PMID: 25455990 
  10. Feng S, Cowling BJ, Sullivan SG. Influenza vaccine effectiveness by test-negative design - Comparison of inpatient and outpatient settings. Vaccine. 2016;34(14):1672-9.  https://doi.org/10.1016/j.vaccine.2016.02.039  PMID: 26920469 
  11. Reber AJ, Chirkova T, Kim JH, Cao W, Biber R, Shay DK, et al. Immunosenescence and challenges of vaccination against influenza in the aging population. Aging Dis. 2012;3(1):68-90. PMID: 22500272 
  12. Sullivan SG, Feng S, Cowling BJ. Potential of the test-negative design for measuring influenza vaccine effectiveness: a systematic review. Expert Rev Vaccines. 2014;13(12):1571-91.  https://doi.org/10.1586/14760584.2014.966695  PMID: 25348015 
  13. McLean HQ, Thompson MG, Sundaram ME, Kieke BA, Gaglani M, Murthy K, et al. Influenza vaccine effectiveness in the United States during 2012-2013: variable protection by age and virus type. J Infect Dis. 2015;211(10):1529-40.  https://doi.org/10.1093/infdis/jiu647  PMID: 25406334 
  14. Skowronski DM, Janjua NZ, De Serres G, Sabaiduc S, Eshaghi A, Dickinson JA, et al. Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses. PLoS One. 2014;9(3):e92153.  https://doi.org/10.1371/journal.pone.0092153  PMID: 24667168 
  15. Simpson CR, Lone NI, Kavanagh K, Ritchie LD, Robertson C, Sheikh A, et al. Trivalent inactivated seasonal influenza vaccine effectiveness for the prevention of laboratory-confirmed influenza in a Scottish population 2000 to 2009. Euro Surveill. 2015;20(8):21043.  https://doi.org/10.2807/1560-7917.ES2015.20.8.21043  PMID: 25742433 
  16. Pebody R, Warburton F, Andrews N, Ellis J, von Wissmann B, Robertson C, et al. Effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2014/15 end of season results. Euro Surveill. 2015;20(36):30013.  https://doi.org/10.2807/1560-7917.ES.2015.20.36.30013  PMID: 26535911 
  17. Rondy M, Launay O, Puig-Barberà J, Gefenaite G, Castilla J, de Gaetano Donati K, et al. European hospital IVE network. 2012/13 influenza vaccine effectiveness against hospitalised influenza A(H1N1)pdm09, A(H3N2) and B: estimates from a European network of hospitals. Euro Surveill. 2015;20(2):21011.  https://doi.org/10.2807/1560-7917.ES2015.20.2.21011  PMID: 25613779 
  18. Cheng AC, Kotsimbos T, Kelly PMFluCAN Investigators. Influenza vaccine effectiveness against hospitalisation with influenza in adults in Australia in 2014. Vaccine. 2015;33(51):7352-6.  https://doi.org/10.1016/j.vaccine.2015.10.016  PMID: 26529066 
  19. Turner N, Pierse N, Bissielo A, Huang Q, Radke S, Baker M, et al. SHIVERS investigation team. Effectiveness of seasonal trivalent inactivated influenza vaccine in preventing influenza hospitalisations and primary care visits in Auckland, New Zealand, in 2013. Euro Surveill. 2014;19(34):20884.  https://doi.org/10.2807/1560-7917.ES2014.19.34.20884  PMID: 25188614 
  20. Kelly HA, Lane C, Cheng AC. Influenza vaccine effectiveness in general practice and in hospital patients in Victoria, 2011-2013. Med J Aust. 2016;204(2):76.e1-4.  https://doi.org/10.5694/mja15.01017  PMID: 26821109 
  21. Martínez-Baz I, Navascués A, Pozo F, Chamorro J, Albeniz E, Casado I, et al. Influenza vaccine effectiveness in preventing inpatient and outpatient cases in a season dominated by vaccine-matched influenza B virus. Hum Vaccin Immunother. 2015;11(7):1626-33.  https://doi.org/10.1080/21645515.2015.1038002  PMID: 25996366 
  22. McLean HQ, Thompson MG, Sundaram ME, Meece JK, McClure DL, Friedrich TC, et al. Impact of repeated vaccination on vaccine effectiveness against influenza A(H3N2) and B during 8 seasons. Clin Infect Dis. 2014;59(10):1375-85.  https://doi.org/10.1093/cid/ciu680  PMID: 25270645 
  23. Martínez-Baz I, Martínez-Artola V, Reina G, Guevara M, Cenoz MG, Morán J, et al. Effectiveness of the trivalent influenza vaccine in Navarre, Spain, 2010-2011: a population-based test-negative case-control study. BMC Public Health. 2013;13(1):191.  https://doi.org/10.1186/1471-2458-13-191  PMID: 23496887 
  24. Castilla J, Martínez-Baz I, Martínez-Artola V, Reina G, Pozo F, García Cenoz M, et al. Decline in influenza vaccine effectiveness with time after vaccination, Navarre, Spain, season 2011/12. Euro Surveill. 2013;18(5):20388.  https://doi.org/10.2807/ese.18.05.20388-en  PMID: 23399423 
  25. Castilla J, Navascués A, Fernández-Alonso M, Reina G, Albéniz E, Pozo F, et al. Effects of previous episodes of influenza and vaccination in preventing laboratory-confirmed influenza in Navarre, Spain, 2013/14 season. Euro Surveill. 2016;20(22):30243.  https://doi.org/10.2807/1560-7917.ES.2016.21.22.30243  PMID: 27277013 
  26. Instituto de Salud Pública y Laboral de Navarra. Protocolo de vacunación antigripal 2015-2016. [Influenza vaccination protocol 2015-2016]. Boletín Informativo. 2015;85:1-4. Spanish. Available from: https://www.navarra.es/NR/rdonlyres/AECCD760-AB2A-4841-818A-FA53478FD6DC/326813/BOL8515.pdf
  27. European Commission. Commission Decision of 28 April 2008 amending Decision 2002/253/EC laying down case definitions for reporting communicable diseases to the Community network under Decision No 2119/98/EC of the European Parliament and of the Council. Luxembourg: Official Journal of the European Union. 18.6.2008:L 159/46. Available from: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2008:159:0046:0090:EN:PDF
  28. Belongia EA, Simpson MD, King JP, Sundaram ME, Kelley NS, Osterholm MT, et al. Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infect Dis. 2016;16(8):942-51.  https://doi.org/10.1016/S1473-3099(16)00129-8  PMID: 27061888 
  29. McLean HQ, Meece JK, Belongia EA. Influenza vaccination and risk of hospitalization among adults with laboratory confirmed influenza illness. Vaccine. 2014;32(4):453-7.  https://doi.org/10.1016/j.vaccine.2013.11.060  PMID: 24291201 
  30. Petrie JG, Ohmit SE, Cheng CK, Martin ET, Malosh RE, Lauring AS, et al. Influenza vaccine effectiveness against antigenically drifted influenza higher than expected in hospitalized adults: 2014-2015. Clin Infect Dis. 2016;63(8):1017-25.  https://doi.org/10.1093/cid/ciw432  PMID: 27369320 
  31. Jackson LA, Jackson ML, Nelson JC, Neuzil KM, Weiss NS. Evidence of bias in estimates of influenza vaccine effectiveness in seniors. Int J Epidemiol. 2006;35(2):337-44.  https://doi.org/10.1093/ije/dyi274  PMID: 16368725 
  32. Carrat F, Vergu E, Ferguson NM, Lemaitre M, Cauchemez S, Leach S, et al. Time lines of infection and disease in human influenza: a review of volunteer challenge studies. Am J Epidemiol. 2008;167(7):775-85.  https://doi.org/10.1093/aje/kwm375  PMID: 18230677 
  33. Martínez-Baz I, Casado I, Navascués A, Díaz-González J, Aguinaga A, Barrado L, et al. Effect of repeated vaccination with the same vaccine component against 2009 pandemic influenza A(H1N1) virus. J Infect Dis. 2017;215(6):847-55.  https://doi.org/10.1093/infdis/jix055  PMID: 28453845 
/content/10.2807/1560-7917.ES.2018.23.2.16-00780
Loading

Data & Media loading...

Comment has been disabled for this content
Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error